Gemcitabine With Curcumin for Pancreatic Cancer

• Status: Completed
• Trial end date: 2010-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The study hypotheasis is that curcumin, a natural compound with a potent antiproliferative effect, can improve the efficacy of the standard chemotherapy gemcitabine in patients with advanced pancreatic cancer. That is why the patients are given a daily oral dose of 8 gr of curcumin along the chemotherapeutic protocol of weekly gemcitabine.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Rambam Health Care Campus
• Treatments: Curcumin; Gemcitabine

Criteria

Inclusion Criteria:

• locally advanced or metastatic adenocarcinoma of the pancreas

• no prior chemotherapy

• performance status 0-2

• adequate hematology and chemistry

Exclusion Criteria:

• serious concurrent medical condition